Bitcoin Group SE's subsidiary, futurum bank AG, was denied authorization under the EU's MiCA regulation, causing trading on Bitcoin.de to be suspended since June 12, 2026. The company plans to resume trading soon by separating trading and custody functions through regulated partners and updating the Bitcoin.de app. Customer assets remain secure, and claims intact during this transition. The licensing refusal followed an application in June 2025, with the company able to appeal or reapply. Meanwhile, Bitcoin Group reported weaker financial results with declining revenue and negative EBITDA expected for 2026.
Bitcoin Group's trading suspension on Bitcoin.de is notable as 37 of 50 major cryptocurrencies on Pluang fell today. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 07, 2026 03:33 WIB: ZIL (Zilliqa) traded at Rp63 with a 1-day change of -3.52% and Pluang order activity showing 28% Sell / 72% Buy, CRV (Curve DAO Token) at Rp6,488 with a -3.47% change and 55% Sell / 45% Buy order activity, and MANA (Decentraland) at Rp1,827 with a -3.13% change and 29% Sell / 71% Buy order activity. Typical hold times on Pluang range from 62 to 156 days among these tokens.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
